Unnamed: 0,title,date,stock,sentiment
683026.0,Shares Of Isoray Tick Higher After Company Announces Second Ten Year Data On Efficacy Of Cesium-131 Internal Radiation Therapy To Treat Prostate Cancer,2020-06-02 08:14:00-04:00,ISR,negative
683027.0,Second Ten Year Data Report Demonstrates Efficacy of Isoray's Cesium-131 Internal Radiation Therapy in the Treatment of Prostate Cancer,2020-06-02 08:13:00-04:00,ISR,negative
683028.0,75 Biggest Movers From Yesterday,2020-05-14 04:26:00-04:00,ISR,neutral
683029.0,50 Stocks Moving In Wednesday's Mid-Day Session,2020-05-13 12:41:00-04:00,ISR,neutral
683030.0,50 Stocks Moving In Wednesday's Mid-Day Session,2020-05-13 12:41:00-04:00,ISR,neutral
683031.0,30 Stocks Moving in Wednesday's Pre-Market Session,2020-05-13 07:17:00-04:00,ISR,neutral
683032.0,"IsoRay Q3 EPS $(0.010), Inline, Sales $2.880M Beat $2.550M Estimate",2020-05-12 16:18:00-04:00,ISR,neutral
683033.0,Centers for Medicare and Medicaid Services Approves Isoray's Application for Billing Codes for the Intraoperative Use of Cesium-131,2020-05-12 16:09:00-04:00,ISR,positive
683034.0,"H.C. Wainwright Reiterates Buy on Isoray, Raises Price Target to $1.25",2020-02-12 07:28:00-05:00,ISR,neutral
683035.0,"IsoRay Q2 EPS $(0.01), Inline, Sales $2.21M Miss $2.31M Estimate",2020-02-11 16:09:00-05:00,ISR,negative
683036.0,81 Biggest Movers From Yesterday,2019-11-14 05:20:00-05:00,ISR,neutral
683037.0,54 Stocks Moving In Wednesday's Mid-Day Session,2019-11-13 12:08:00-05:00,ISR,neutral
683038.0,44 Stocks Moving in Wednesday's Pre-Market Session,2019-11-13 07:19:00-05:00,ISR,neutral
683039.0,Isoray shares are trading higher after the company reported better-than-expected Q3 EPS and sales results.,2019-11-12 16:59:00-05:00,ISR,positive
683040.0,"IsoRay Q1 EPS $(0.01) Beats $(0.02) Estimate, Sales $2.32M Beat $1.95M Estimate",2019-11-12 16:24:00-05:00,ISR,neutral
683041.0,"IsoRay Q4 EPS $(0.02) Up From $(0.04) YoY, Sales $1.92M Miss $2.02M Estimate",2019-09-24 16:06:00-04:00,ISR,negative
683042.0,"Earnings Scheduled For September 24, 2019",2019-09-24 03:50:00-04:00,ISR,neutral
683043.0,IsoRay Highlights Recent Publication Of Report On Study Of 10-Year findings On Impact Of Cesium-131 Therapy,2019-09-18 08:19:00-04:00,ISR,neutral
683044.0,"Isoray Granted U.S. Patent Number 10,328,278 Titled 'Device For Loading Brachytherapy Seeds Into Implantation Sleeves'",2019-06-25 13:55:00-04:00,ISR,positive
683045.0,Isoray Filing Shows Registration For 5.83M Share Common Stock Offering Via Selling Shareholders,2019-05-13 17:14:00-04:00,ISR,positive
683046.0,"IsoRay Q3 EPS $(0.02), Inline, Sales $1.92M Beat $1.86M Estimate",2019-05-09 17:29:00-04:00,ISR,neutral
683047.0,"IsoRay Q2 EPS $(0.02) Beats $(0.03) Estimate, Sales $1.904M Beat $1.6M Estimate",2019-02-12 16:46:00-05:00,ISR,neutral
683048.0,"H.C. Wainwright Assumes IsoRay, Inc. Common Stock (DE) at Buy, Announces Price Target $0.70",2019-01-28 08:26:00-05:00,ISR,neutral
683049.0,IsoRay Announces Lori Woods CEO,2018-12-17 08:18:00-05:00,ISR,neutral
683050.0,IsoRay Names Jonathan Hunt New Chief Financial Officer,2018-12-03 08:14:00-05:00,ISR,neutral
683051.0,"Maxim Group Downgrades IsoRay, Inc. Common Stock to Hold",2018-11-09 08:48:00-05:00,ISR,neutral
683052.0,"IsoRay, Inc. Q1 EPS $(0.02) Up From $(0.03) YoY, Sales $1.562M Miss $1.8M Estimate",2018-11-08 16:40:00-05:00,ISR,negative
683053.0,"IsoRay Q4 EPS $(0.04) Misses $(0.03) Estimate, Sales $1.6M Beat $1.55M Estimate",2018-09-25 16:05:00-04:00,ISR,negative
683054.0,"Earnings Scheduled For September 25, 2018",2018-09-25 04:51:00-04:00,ISR,neutral
683055.0,"H.C. Wainwright Initiates Coverage On IsoRay, Inc. Common Stock with Neutral Rating, Announces $1 Price Target",2018-08-20 10:24:00-04:00,ISR,neutral
683056.0,41 Biggest Movers From Yesterday,2018-07-11 04:38:00-04:00,ISR,neutral
683057.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Tues., Jul. 10, 2018",2018-07-10 15:48:00-04:00,ISR,positive
683058.0,Mid-Afternoon Market Update: OncoCyte Surges Following Positive DetermaVu Study Results; IsoRay Shares Drop,2018-07-10 15:28:00-04:00,ISR,positive
683059.0,32 Stocks Moving In Tuesday's Mid-Day Session,2018-07-10 12:20:00-04:00,ISR,neutral
683060.0,Mid-Day Market Update: Dow Rises Over 150 Points; Spero Therapeutics Shares Plunge,2018-07-10 12:19:00-04:00,ISR,positive
683061.0,Mid-Morning Market Update: Markets Open Higher; PepsiCo Beats Q2 Expectations,2018-07-10 10:15:00-04:00,ISR,neutral
683062.0,IsoRay Shares Down 40% After Spiking Monday On FDA Clearance Of GammaTile Therapy Treatment; Co. Announced $8.25M Registered Direct Offering,2018-07-10 09:00:00-04:00,ISR,positive
683063.0,30 Biggest Movers From Yesterday,2018-07-10 05:02:00-04:00,ISR,neutral
683064.0,IsoRay Announces $8.25M Registered Direct Offering; Tto Sell 11M Shares to Several Investors for $0.75/Share,2018-07-09 20:10:00-04:00,ISR,positive
683065.0,IsoRay Shares Resume Trade Up 115.5% At $0.93,2018-07-09 14:06:00-04:00,ISR,positive
683067.0,28 Stocks Moving In Monday's Mid-Day Session,2018-07-09 12:16:00-04:00,ISR,neutral
683068.0,IsoRay Shares Now Up 51.6% Amid Rumors That Co.'s GammaTile Won FDA 510(K) Approval,2018-07-09 10:57:00-04:00,ISR,positive
683069.0,IsoRay Shares Halted News Pending,2018-07-09 10:41:00-04:00,ISR,positive
683070.0,"IsoRay Shares Resume Trade, Continue Higher, Now Up 116%",2018-07-09 09:51:00-04:00,ISR,positive
683071.0,"IsoRay Shares Halted On Circuit Breaker, Up 88.6%",2018-07-09 09:46:00-04:00,ISR,positive
683072.0,UPDATE: IsoRay Shares Now Up 75% For Session,2018-07-09 09:45:00-04:00,ISR,positive
683073.0,IsoRay Shares Spike ~$0.19 On Heavy Volume As Traders Circulating Chatter Co.'s GammaTile Won FDA 510(K) Approval,2018-07-09 09:45:00-04:00,ISR,positive
683074.0,IsoRay Reports 1-Year Employment Contract With Interim CEO,2018-06-19 08:10:00-04:00,ISR,neutral
683075.0,IsoRay Announces the Resignation of Chairman and CEO Thomas LaVoy; Industry Veteran Lori Woods Appointed Interim CEO; Mick McCormick Appointed Chairman of the Board,2018-06-05 08:01:00-04:00,ISR,negative
683076.0,IsoRay Appoints Lori Woods As Interim CEO,2018-06-05 06:39:00-04:00,ISR,neutral
683077.0,IsoRay Announces Departure Of CEO Thomas LaVoy,2018-06-05 06:38:00-04:00,ISR,neutral
683078.0,Isoray Shares Up 32.9% After Co. Announced Release Of Build-Blu Delivery System For Real-Time Prostate Brachytherapy,2018-05-11 13:01:00-04:00,ISR,positive
683079.0,"IsoRay Reports Release Of Build-Blu Delivery System For Real-Time Prostate Brachytherapy; Highlights Intra-Operative Segment Accounts For 25%, Or $25M Of Prostate Brachytherapy Market",2018-05-11 08:39:00-04:00,ISR,neutral
683080.0,"IsoRay Q3 EPS $(0.02) Beats $(0.03) Estimate, Sales $1.573M Beat $1.54M Estimate",2018-05-03 17:37:00-04:00,ISR,neutral
683081.0,"IsoRay Sees Q3 Sales $1.57M vs $1.52M Est., Gross Profit $610K vs $290K In Same Qtr. Last Year",2018-04-18 08:31:00-04:00,ISR,negative
683082.0,"Ascendiant Capital Earlier Initiated Coverage On IsoRay, Inc. Common Stock with Buy Rating, Announced $1.00 Price Target",2018-04-02 13:21:00-04:00,ISR,neutral
683083.0,"Benzinga's Top Upgrades, Downgrades For April 2, 2018",2018-04-02 09:12:00-04:00,ISR,positive
683084.0,Ascendiant Capital Initiates Isoray With Buy; PT $1‍​,2018-04-02 04:00:00-04:00,ISR,neutral
683085.0,"IsoRay Reports Q2 EPS $(0.03) vs $(0.02) Est., Sales $1.54M In-line With Est.",2018-02-08 16:41:00-05:00,ISR,neutral
683086.0,IsoRay Announces Q2 Prelim. Sales Of $1.54M vs $1.37M Est.,2018-01-24 08:12:00-05:00,ISR,neutral
683087.0,IsoRay Reports Publication Of Report Discussing Focal Radiation Treatment Of Brain Metastases With Cesium-131: 'Possible Evidence of Paradigm Shift in the Radiation Treatment of Cancers Afflicting the Brain',2018-01-09 08:06:00-05:00,ISR,neutral
683088.0,IsoRay Earlier Announced 10-Year Mfg. and Supply Agreement With GT Medical Tech,2018-01-08 11:56:00-05:00,ISR,positive
683089.0,"IsoRay Reports Q1 EPS $(0.03), Revenue $1.21M vs. $1.08M In The Same Qtr. Last Year",2017-11-14 16:31:00-05:00,ISR,neutral
683090.0,"IsoRay Announces the Launch of a Phase II, Multicenter Clinical Trial with Cesium-131 Adjuvant Radiation for Retroperitoneal Sarcoma Delivery System by University of Louisville",2017-11-09 08:11:00-05:00,ISR,neutral
683091.0,Isoray Reports Q4 Sales $1.37M vs $1.12M IN Prior Year Quarter,2017-09-28 08:04:00-04:00,ISR,neutral
683092.0,Isoray Says ‍on Aug 25 Isoray Medical Unit Entered Into Consignment Agreement With Medikorpharma-Ural Llc,2017-08-31 06:16:00-04:00,ISR,positive
683093.0,IsoRay Names Mark Austin Principal Accounting and Financial Officer,2017-07-07 08:00:00-04:00,ISR,neutral
683094.0,IsoRay Reports That The FDA Indicated The Need For Its Co-Applicant GammaTile To Submit Additional Data Within Next 180 Days As Condition For Securing FDA Clearance,2017-07-06 08:07:00-04:00,ISR,positive
683095.0,IsoRay Reports Publication Of Study Considering Intraoperative Cesium-131 Bracytherapy: 42 Patients With Total Of 46 Metastases >2 cm In Preoperative Diameter Were Accrued Onto Prospective Trial Over 5 Years,2017-06-20 08:07:00-04:00,ISR,neutral
683096.0,"IsoRay Reports Q3 EPS $(0.02) vs $(0.02) In Prior Year Period, Sales $1.28M vs $1.20M In Prior Year Period",2017-05-10 08:12:00-04:00,ISR,neutral
683097.0,IsoRay Reports Final Court Approval of Class Action Settlement,2017-03-09 16:19:00-05:00,ISR,positive
683098.0,"IsoRay Reports Q2 EPS $(0.03), Revenue $1.03M",2017-02-08 16:43:00-05:00,ISR,neutral
683099.0,IsoRay CFO Brien Ragle Announces Resignation -8K,2017-01-17 06:25:00-05:00,ISR,negative
683100.0,IsoRay Announces Pilot Study for Cesium-131,2016-12-21 08:33:00-05:00,ISR,neutral
683101.0,"IsoRay Announces ""Cesium-131 Brachytherapy for Salvage of Recurrent High Grade Glioma"" Poster Presentation at 21st Annual Scientific Meeting of Society for Neuro-Oncology",2016-11-29 09:05:00-05:00,ISR,neutral
683102.0,"IsoRay Files Class Action Lawsuit for $3.54M, Expects Amount to Be Paid By Insurance",2016-09-27 06:10:00-04:00,ISR,negative
683103.0,IsoRay Announces Agreement to Settle Class Action Shareholder Litigation,2016-09-27 06:03:00-04:00,ISR,positive
683104.0,A Peek Into The Markets: U.S. Stock Futures Gain; Yellen Speech In Focus,2016-06-21 07:48:00-04:00,ISR,positive
683105.0,IsoRay Reports Results of Prospective Trial: '95% of Targeted Cancers Showed No Regrowth of Tumor at the Operative Site',2016-06-21 06:31:00-04:00,ISR,negative
683106.0,UPDATE: IsoRay Says Trial Date Has Not Yet Been Set,2016-06-02 16:25:00-04:00,ISR,neutral
683107.0,"UPDATE: IsoRay Says Judge Ruled Order Did Not Adjudicate Merits of Suit, No Other Issues Were Decided in Ruling",2016-06-02 16:22:00-04:00,ISR,negative
683108.0,UPDATE: IsoRay Says Judge Ruled Complaint's Allegations State Plausible Claim to Relief,2016-06-02 16:21:00-04:00,ISR,positive
683109.0,IsoRay Reports Court Ruling on Co.'s Motion to Dismiss Securities Suit: Judge Suko Entered Order Denying Dismissal Motion,2016-06-02 16:21:00-04:00,ISR,negative
683110.0,"IsoRay Provides Update on Motion to Dismiss Securities Lawsuit, Court Did Not Provide Specific Time Frame Or Date For Pending Securities Lawsuit To Be Issued",2016-05-16 09:02:00-04:00,ISR,positive
683111.0,"IsoRay Reports Q3 EPS $(0.02) Vs Prior $(0.02), Sales $1.199M Vs Prior $1.158M",2016-05-10 16:56:00-04:00,ISR,neutral
683112.0,"Chairman Lavoy Buys 36,706 Shares of IsoRay @$0.89/Share -Form 4",2016-03-16 05:42:00-04:00,ISR,positive
683113.0,"Director McCormick Buys 22,000 Shares of IsoRay @$0.87/Share -Form 4",2016-03-10 05:10:00-05:00,ISR,positive
683114.0,"IsoRay Reports Q2 EPS $(0.02) Vs Prior $(0.02), Sales $1.189M Vs Prior $1.065M",2016-02-10 08:03:00-05:00,ISR,neutral
683115.0,"IsoRay Names Thomas LaVoy CEO, Effective Feb. 15",2016-01-14 08:05:00-05:00,ISR,positive
683116.0,"IsoRay Reports Chair, CEO Dwight Babcock to Retire; Bill Cavanagh to Serve as Interim CEO, Tom LaVoy Named Chair",2016-01-07 08:11:00-05:00,ISR,neutral
683117.0,Weill Cornell Medical Clinical Study Shows Cesium-131 Brachytherapy Seeds on a String Surgical Technique Promotes Dose Homogeneity & Minimizes the Risk of Radiation-Induced Injury,2015-12-16 08:31:00-05:00,ISR,negative
683118.0,"IsoRay Notes Weill Cornell Clinical Study Of Cesium-131 Brachytherapy Provides Viable Alternative TO Whole Brain Radiotherapy, Notes Great Response Rates & Low Toxicity",2015-12-14 08:35:00-05:00,ISR,positive
683119.0,IsoRay Reports Q1 EPS $(0.02) vs $0.01 Est.,2015-11-10 08:40:00-05:00,ISR,neutral
683120.0,"IsoRay Reports FY15 Sales Up 9% to $4.606M, Loss of $0.07/Share; Q4 Loss of $0.02/Share, Sales $1.34M",2015-09-15 08:17:00-04:00,ISR,negative
683121.0,"8-K filing: IsoRay Medical, Inc. , a wholly owned subsidiary of IsoRay, Inc. , entered into an International Distribution Agreementwith Karlheinz Goehl-Medizintechnik Goehl",2015-09-02 17:23:00-04:00,ISR,neutral
683122.0,S-3 from IsoRay Shows Registration for $20M Mixed Securities Shelf Offering,2015-08-25 16:07:00-04:00,ISR,positive
683123.0,IsoRay's Cesium-131 Cancer Fighting Portfolio was on Display at the American Association of Physicists in Medicine (AAPM) Convention,2015-07-16 08:31:00-04:00,ISR,negative
683124.0,IsoRay's Cesium-131 Cancer Fighting Portfolio was on Display at the American Association of Physicists in Medicine  Convention,2015-07-16 08:30:00-04:00,ISR,negative
683125.0,IsoRay's Cesium-131 Selected by Chicago Prostate Cancer Center for Use in the Launch of a Study of the Focal Treatment of Prostate Cancer,2015-06-29 08:34:00-04:00,ISR,negative
683126.0,IsoRay Announces Intention to 'Vigorously Defend Litigation',2015-06-23 08:32:00-04:00,ISR,negative
683127.0,Spike in IsoRay May be Attributed to Posting on BioPortfolio: 'Surgical Resection and Intraoperative Cesium-131 Brachytherapy for Head and Neck Cancer',2015-06-11 14:33:00-04:00,ISR,negative
683128.0,IsoRay Spikes Higher,2015-06-11 14:30:00-04:00,ISR,neutral
683129.0,"Isoray Chairman Babcock Buys 10,000 Shares @$1.53/Share -Form 4",2015-06-09 19:14:00-04:00,ISR,positive
683130.0,IsoRay's Intra-Cranial Brachytherapy Brain Cancer Treatments Using Cesium-131 Were Showcased at the Brain Tumor Biotech Summit 2015,2015-06-01 08:16:00-04:00,ISR,negative
683131.0,UPDATE: IsoRay Shares Now Up 95% Following Report on Cesium-131 Lung Cancer Treatment,2015-05-20 14:11:00-04:00,ISR,negative
683132.0,Morning Market Gainers,2015-05-20 09:43:00-04:00,ISR,neutral
683133.0,IsoRay's Cesium-131 Lung Cancer Treatment Reports 96% Success in Local Control and 100% Survival at 5 Years in High Risk Patients in Newly Published Report,2015-05-20 08:16:00-04:00,ISR,negative
683134.0,"IsoRay Reports Q3 Loss of $0.02/Share vs Loss of $0.01/Share Est., Sales $1.158M vs $1.6M Est.",2015-05-18 08:46:00-04:00,ISR,negative
683135.0,IsoRay Shares Move Higher; May be Attributed to Tweet: $ISR $MRK Isoray Cesium-131 5/8 2:30PM Study ...implants resulted in no local recurrences and no radiation necrosis.,2015-05-06 12:24:00-04:00,ISR,negative
683136.0,IsoRay Shares Move Higher; May be Attributed to Seeking Alpha Post,2015-04-29 12:36:00-04:00,ISR,positive
683137.0,‏@Isoray Medical Tweet: Cs-131 Brachy Therapy: Take the Cancer out without harming healthy tissue #CancerSucks #radiology #CancerCare,2015-04-21 14:10:00-04:00,ISR,negative
683138.0,"IsoRay's Cancer Fighting Isotope Cesium-131 Will Be Showcased in Four Oral Presentations at American Brachytherapy Society (ABS) Convention in Orlando, Florida",2015-04-08 08:32:00-04:00,ISR,negative
683139.0,"Spokesperson for Preston Robert Tisch Brain Tumor Center at Duke University Says Brain Cancer Trial Being Mentioned in 60 Minutes Segment is Specific to Duke, They Do Not Have a Partner",2015-03-27 12:58:00-04:00,ISR,negative
683140.0,60 Minutes Would Not Confirm Novogen Would be Mentioned in Upcoming 2-Part Segment on Brain Cancer Treatment,2015-03-27 10:20:00-04:00,ISR,negative
683141.0,Morning Market Gainers,2015-03-24 09:40:00-04:00,ISR,neutral
683142.0,Gynecologic Cancers Successfully Treated Using IsoRay's Cesium-131 tol Be Presented at Society of Gynecologic Oncology Convention,2015-03-24 08:05:00-04:00,ISR,positive
683143.0,"IsoRay Q2 EPS Loss of $0.02, Rev. $1.06M",2015-02-18 08:20:00-05:00,ISR,negative
683144.0,Tuesday's Morning Movers: FXCM Takes Another Big Drop,2015-01-20 09:44:00-05:00,ISR,negative
683145.0,UPMC Study Reports IsoRay's Cesium-131 Prostate Treatment Provides Strong Cancer Control With Lower Side Effects,2015-01-20 08:21:00-05:00,ISR,negative
683146.0,IsoRay Shares Up 20% Amid Positive Brain Cancer Treatment Results,2014-12-01 10:36:00-05:00,ISR,positive
683147.0,Morning Market Movers,2014-12-01 09:39:00-05:00,ISR,neutral
683148.0,IsoRay Shares Rise 33% Premarket on Report  Cesium-131 Therapy Stops Brain Cancers from Recurring in Treated Locations Where Previous Conventional Treatments Failed,2014-12-01 08:57:00-05:00,ISR,negative
683149.0,"IsoRay, Inc. Reports Q1 EPS of $(0.01), Inline; Revenue of $1.04M vs $1.04M Est",2014-11-17 08:49:00-05:00,ISR,neutral
683150.0,Benzinga's Weekend M&A Chatter,2014-10-26 21:15:00-04:00,ISR,neutral
683151.0,Hearing Deal Reporter Says Varian Medical Interested in IsoRay,2014-10-24 09:42:00-04:00,ISR,positive
683152.0,"IsoRay, Inc. Reports Success In Brain Cancer Treatment, Shares Up Sharply",2014-10-07 11:34:00-04:00,ISR,positive
683153.0,Morning Market Movers ,2014-10-07 09:41:00-04:00,ISR,neutral
683154.0,Isoray Announces Early Success for Young Peruvian Girl Utilizing Cesium-131 In First Stereotactic Implant For Inoperable Brain Cancer,2014-10-07 08:21:00-04:00,ISR,negative
683155.0,Morning Market Losers ,2014-09-30 09:51:00-04:00,ISR,negative
683156.0,"IsoRay, Inc. Reports FY EPS of $(0.16), Down 45% YOY; Revenue of $4.22M, Down 7% YOY",2014-09-30 08:49:00-04:00,ISR,neutral
683157.0,IsoRay Announces Positive Peer Review Of Cesium-131 In Treatment Of Metastatic Brain Cancer,2014-08-05 15:05:00-04:00,ISR,negative
683158.0,IsoRay Announces First Cesium-131 Delivery for Treatment of Inoperable Brain Cancer in Young Child in Peru ,2014-07-14 08:37:00-04:00,ISR,negative
683159.0,Isoray Spikes Higher; May be Attributed to Aetna Bulletin Circulating Regarding Brachytherapy Being Covered,2014-06-26 13:19:00-04:00,ISR,neutral
683160.0,Morning Market Movers ,2014-06-24 09:40:00-04:00,ISR,neutral
683161.0,IsoRay Announces New Russian and Peruvian International Distributor Agreements for Full Line of Products ,2014-06-20 09:03:00-04:00,ISR,positive
683162.0,Hearing Unconfirmed Market Chatter Circulating in Chat Rooms of Potential JNJ Interest in Isoray,2014-06-05 11:01:00-04:00,ISR,positive
683163.0,"IsoRay, Inc. Reports Q3 EPS of $(0.05) vs $(0.03) Est",2014-05-16 09:43:00-04:00,ISR,neutral
683164.0,Morning Market Movers ,2014-05-12 09:39:00-04:00,ISR,neutral
683165.0,UPDATE: IsoRay Announces Co.'s Liquid Cesium-131 Has Received Final Regulatory Approval for Use in GliaSite Brain Cancer Treatment System,2014-05-12 09:09:00-04:00,ISR,negative
683166.0,IsoRay Announces Co.'s Liquid Cesium-131 Has Received Final Regulatory Approval for Use in GliaSite Brain Cancer Treatment System,2014-05-12 09:07:00-04:00,ISR,negative
683167.0,Morning Market Movers ,2014-04-30 09:43:00-04:00,ISR,neutral
683168.0,Morning Market Movers ,2014-04-07 09:40:00-04:00,ISR,neutral
683169.0,"UPDATE: IsoRay Shares Rise 8.5% Premarket as Company Announces Human Prostate Implant Utilizing Cesium-131 Seeds, C4 Imaging's Positive Signal MRI Markers",2014-04-07 09:07:00-04:00,ISR,positive
683170.0,Morning Market Movers ,2014-04-01 09:43:00-04:00,ISR,neutral
683171.0,UPDATE: IsoRay Announces Five Presentations at ABS Convention on Ongoing Success of Cesium-131 in Fighting Cancer,2014-04-01 09:08:00-04:00,ISR,negative
683172.0,Isoray Shares Rise 21% Premarket. May be Attributed to Cesium 131 Presentation Announcement ,2014-04-01 09:06:00-04:00,ISR,positive
683173.0,IsoRay Prices 5.64M Shares at $2.60/Share,2014-03-21 09:28:00-04:00,ISR,positive
683174.0,Morning Market Movers ,2014-03-20 09:39:00-04:00,ISR,neutral
683175.0,UPDATE: Isoray Shares Rise Another 25% Premarket Following Wednesday's PR on First Pediatric Cesium-131 Seeded Mesh Treatment for Metastatic Wilms Tumor,2014-03-20 09:21:00-04:00,ISR,negative
683176.0,Benzinga's Top #PreMarket Gainers,2014-03-20 08:08:00-04:00,ISR,positive
683177.0,Momentum for IsoRay Shares Continues After Co. Announces First Pediatric Cesium-131 Seeded Mesh Treatment for Metastatic Wilms Tumor,2014-03-20 07:59:00-04:00,ISR,negative
683178.0,Isoray Spikes Higher; May be Attributed to Seeking Alpha Post,2014-03-14 11:48:00-04:00,ISR,neutral
683179.0,IsoRay Receives Greek Governmental Approval for Sales of Entire Product Line,2014-03-11 09:31:00-04:00,ISR,positive
683180.0,"IsoRay, Inc. Reports Q2 EPS of $(0.02), Inline",2014-02-18 09:31:00-05:00,ISR,neutral
683181.0,"Maxim Group Initiates Coverage on IsoRay, Inc. at Buy, Announces $1.50 PT",2013-11-01 10:30:00-04:00,ISR,neutral
683182.0,"Earnings Scheduled For September 27, 2013",2013-09-27 04:14:00-04:00,ISR,neutral
683183.0,"IsoRay, Inc. Reports Q3 EPS of $(0.02) vs $(0.03) Est",2013-05-15 09:25:00-04:00,ISR,neutral
683184.0,"IsoRay, Inc. Reports Q2 EPS of $(0.03), Inline; Revenue of $975.45K vs $1.32M Est",2013-02-14 09:15:00-05:00,ISR,neutral
683185.0,"Benzinga's Small Cap Movers for Tuesday December 11, 2012",2012-12-11 19:09:00-05:00,ISR,neutral
683186.0,IsoRay Plummets 20% on New Financing,2012-07-16 14:10:00-04:00,ISR,neutral
683187.0,Morning Market Losers,2012-07-16 09:52:00-04:00,ISR,negative
683188.0,IsoRay Announces Financing of $3.5 Million to Advance Its GliaSite and New Emerging Cancer Solutions for Internal Radiation Therapy  ,2012-07-16 09:01:00-04:00,ISR,negative
683189.0,IsoRay Announces First International Orders for GliaSite Radiation Therapy System  ,2012-07-11 07:53:00-04:00,ISR,neutral
683190.0,IsoRay Rises 15% Pre-Market on Announcement of Cesium-131 Mesh Treatment for Meningioma Brain Tumors,2012-06-05 08:10:00-04:00,ISR,neutral
683191.0,IsoRay Announces World's First Cesium-131 Mesh Treatment for Meningioma Brain Tumors  ,2012-06-05 08:06:00-04:00,ISR,neutral
683192.0,"Benzinga's Microcap Movers for Tuesday May 29, 2012",2012-05-30 08:05:00-04:00,ISR,neutral
683193.0,IsoRay's GliaSite Approved for Sale in 31 European Countries   ,2012-05-22 08:06:00-04:00,ISR,positive
683194.0,"Big Picture, Small Cap Investing: Jim Letourneau",2012-04-03 04:00:00-04:00,ISR,neutral
683195.0,The Nuclear Revival: Mark Lackey,2012-03-08 03:00:00-05:00,ISR,neutral
683196.0,UPDATE: Citigroup Raises Target to $11 on Spectranetics,2012-02-02 12:02:00-05:00,ISR,neutral
683197.0,The Uranium Industry Is Alive and Well: David Talbot,2011-12-13 03:00:00-05:00,ISR,positive
683198.0,WestPark Capital Announces $2.6 Million IsoRay Offering ,2011-12-02 09:30:00-05:00,ISR,neutral
683199.0,IsoRay Receives Final Regulatory Approval for GliaSite Brain Cancer Treatment   ,2011-11-22 07:47:00-05:00,ISR,negative
683200.0,IsoRay Announces Major International Distribution Agreement for GliaSite,2011-11-03 07:44:00-04:00,ISR,positive
683201.0,MD Anderson Cancer Center Initiates Orders of IsoRay's Cesium-131 for Intermediate Risk Prostate Cancer Study   ,2011-10-10 07:49:00-04:00,ISR,negative
683202.0,CACI Awarded $33.6 Million Task Order to Provide Irregular Warfare Technologies Support for U.S. Navy   ,2011-09-19 08:00:00-04:00,ISR,positive
683203.0,Morning Market Movers,2011-09-12 09:47:00-04:00,ISR,neutral
683204.0,"Financial Breakfast: Morning News Summary for September 12, 2011",2011-09-12 07:52:00-04:00,ISR,neutral
683205.0,FDA Clears IsoRay's GliaSite Treatment for Brain Cancer   ,2011-09-12 07:30:00-04:00,ISR,negative
683206.0,"Dahlman Rose Reaffirms Uranerz Energy Buy, $5 PT",2011-07-20 14:52:00-04:00,ISR,positive
683207.0,"C.K. Cooper Reiterates Isoray Buy, $2 PT",2011-07-12 10:27:00-04:00,ISR,neutral
683208.0,Morning Market Movers,2011-07-12 09:47:00-04:00,ISR,neutral
683209.0,IsoRay Announces World's First Cesium-131 Treatment for Lung Cancer Using da Vinci Robotic Surgery System ,2011-07-12 07:32:00-04:00,ISR,negative
683210.0,*isoray Acquires Exclusive Worldwide License For Liquid Iodine,2011-06-07 07:31:00-04:00,ISR,positive
683211.0,"IsoRay, Inc. Receives $500,000 in Additional Financing   ",2011-04-12 07:31:00-04:00,ISR,neutral
683212.0,Goodrich Provides Enhanced Intelligence Sharing to UK Ministry of Defence ,2011-03-14 09:05:00-04:00,ISR,positive
683213.0,Three Ways to Invest in Nuclear Power,2011-02-28 11:35:00-05:00,ISR,neutral
683214.0,Three Ways to Invest in Nuclear Power,2011-02-28 11:35:00-05:00,ISR,neutral
683215.0,Raytheon To Acquire Applied Signal  - Analyst Blog,2010-12-21 09:36:00-05:00,ISR,neutral
683216.0,Raytheon To Acquire Applied Signal  - Analyst Blog,2010-12-21 09:00:00-05:00,ISR,neutral
683217.0,Uranium Energy Receives Mine Permit And Production Area Authorization (UEC),2010-12-14 12:37:00-05:00,ISR,positive
683218.0,Goodrich to Supply DB-110 to Egypt - Analyst Blog,2010-11-22 18:18:00-05:00,ISR,neutral
683219.0,Goodrich to Supply DB-110 to Egypt - Analyst Blog,2010-11-22 12:40:00-05:00,ISR,neutral
683220.0,Biotech Sector Weekly Rewind,2010-11-20 08:00:00-05:00,ISR,neutral
683221.0,IsoRay Beats by a Penny - Analyst Blog,2010-11-18 14:03:00-05:00,ISR,neutral
683222.0,IsoRay Beats by a Penny - Analyst Blog,2010-11-18 08:30:00-05:00,ISR,neutral
683223.0,Department of Homeland Security Sued Over Boeing Contract,2010-11-01 07:50:00-04:00,ISR,positive
683224.0,IsoRay Posts Q4 Results,2010-09-28 07:47:00-04:00,ISR,neutral
683225.0,Earnings Watch: Stocks Under $5,2010-09-28 07:34:00-04:00,ISR,neutral
683226.0,Couple of Contracts for L-3 - Analyst Blog,2010-07-21 13:06:00-04:00,ISR,neutral
683227.0,Raytheon Gets $6M Defense Funding - Analyst Blog,2010-07-08 12:54:00-04:00,ISR,positive
683228.0,IsoRay (ISR) Shares To Appreciate,2010-05-13 11:39:00-04:00,ISR,positive
683229.0,3-10-10 Daily Small Cap Market News and Stock Highlights from SmallCapVoice.com,2010-03-10 11:51:00-05:00,ISR,neutral
683230.0,L-3 Targets Insight - Analyst Blog,2010-02-24 14:08:00-05:00,ISR,neutral
683231.0,L-3 Comm Raises Dividend - Analyst Blog,2010-02-04 12:33:00-05:00,ISR,neutral
683232.0,IsoRay Stock Soaring! (ISR),2010-01-21 11:18:00-05:00,ISR,neutral
683233.0,General Dynamics Wins Contract - Analyst Blog,2010-01-18 15:25:00-05:00,ISR,positive
683234.0,Uranerz Signs Long-term Contract For Sale of Uranium,2009-08-17 08:30:00-04:00,ISR,neutral
683235.0,Uranerz Reports Independent NI 43-101 Uranium Resources on South Doughstick Property of Arkose Mining Venture,2009-08-14 08:30:00-04:00,ISR,neutral
683236.0,Crosshair Announces Initial Uranium Resource at Bootheel,2009-08-13 08:30:00-04:00,ISR,neutral
683237.0,Denison Mines Corp. Reports Second Quarter Earnings,2009-08-12 17:00:00-04:00,ISR,neutral
683238.0,Ur-Energy Identifies New Exploration Targets With Potential for Additional 24-28 Million Pounds U3O8 in the Lost Creek Area,2009-08-12 13:15:00-04:00,ISR,negative
